University of Ioannina
Empirical assessment of the discrimination ability of cardiovascular disease risk prediction models for mortality
Abstract
dc:descriptionPrognostic tools should be evaluated in several sequential stages: initial model performance (model development), prospective validation in independent cohorts (external validation of a model), impact on patient management and outcome and cost-effectiveness. However, even for established and widely used prognostic tools, many of these steps suffer from methodological limitations and in many cases are missing. Moreover, it is important to highlight the paucity of evidence around their impact on patient management and clinical outcomes. Such important evidence would ideally come from randomized control trials (RCTs), which compare the outcomes of patients whose management is guided by the proposed prognostic tool with the outcomes of patients who are managed without it. However, there are so many prognostic tools, that it is impossible to evaluate all of them in RCTs. Efforts should focus around those with most promising results. In selecting which models to test in randomized trials, one may wish to consider not only satisfactory, validated discriminating ability, but also what is the respective change in disease management that can be anticipated; how effective are the available preventive or treatment interventions for the disease and how much room exists for improvement; what is the expected cost to get the information required for building the model, and to implement it in practice; and how likely it is that the model can be used widely by non-expert health practitioners. Going through such a checklist is likely to eliminate the large majority of proposed prognostic models. Nevertheless, there are currently no randomized trials assessing the implementation of any cardiovascular prediction models. Such studies should be encouraged. A more through and systematic research agenda would be useful to build surrounding late implementation issues, including ease of use, and impact on resources in diverse settings.The bottom line is that the best test of a prediction model is not accuracy but improved clinical outcomes. Compared with clinician judgment, a prediction model might improve diagnostic accuracy, reduce costs and harms, and lead to improved health outcomes. Documenting this benefit requires RCTs in which providers are randomized to use the proposed prediction model or not, and the outcome is improved health. Very few models have been tested in this way. Prediction of risk is not enough—we need evidence that prediction can lead to actions that reduce risk beyond what would occur without the prediction rule.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Siontis, Georgios
- Σιόντης, Γεώργιος
Subjects
dc:subject × 16- Προγνωστικά μοντέλα
- Καρδιοαγγειακά νοσήματα
- Διακριτική ικανότητα
- Εσωτερική επικύρωση
- Εξωτερική επικύρωση
- Prognostic models
- Cardiovascular diseases
- Discriminatory ability
- Internal validation
- External validation
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Επιστήμες Υγείας
- Medical and Health Sciences
- Clinical Medicine
- Health Sciences
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41448